ProStrakan appoints Tom Stratford as CEO
This article was originally published in Scrip
ProStrakan Group, a subsidiary of Kyowa Hakko Kirin and a speciality pharmaceutical company, has appointed Dr Tom Stratford chief executive officer. Dr Stratford takes over from Peter Allen, who has been acting chief executive since September 2010 and will revert to his role as non-executive chairman. Dr Stratford most recently served as executive vice-president of business development for ProStrakan.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.